Teva Pharmaceuticals’ new olanzapine option is the first once-monthly subcutaneous injectable on the market for schizophrenia.
Feature|Articles|January 29, 2026
Work Pressure Continues to Impact Pharmacists’ Suicide Risk, Mental Health
Author(s)Brian Nowosielski
As pharmacists continue to take on greater clinical roles, the growing need to address mental health concerns is reaching a boiling point.
Advertisement
Advertisement
According to a study published in the American Journal of Health-System Pharmacy (AJHP), pharmacists are 21% more likely to die by suicide than individuals in the general population.1 With these suicide trends stemming from a plethora of industry concerns—from the COVID-19 pandemic to current pressures and stigmas—the need for increased suicide awareness and prevention is crucial for pharmacists and technicians across the globe.
Related to this article
Therapy is aimed at decreasing pathogenic IgA production and immune complex formation as well as managing the effects of existing nephron loss.
Harini Bupathi, Esq, joins to discuss the impacts of PBM network terminations and how pharmacies can recover financially.
Pharmacists expand access with no-appointment care but face state laws limiting test-to-treat for COVID-19 and flu, fueling calls for advocacy.
AJ Barbarito, Esq, provides nuance to the evolving pharmacy reimbursement landscape and how PBMs and pharmacies alike are adapting as they approach 2027.
Nicole Pezzino, PharmD, BCACP, BC-ADM, CDCES, details how pharmacies can utilize the booming GLP-1 medication class for greater revenue opportunities.
Matt Martin, PharmD, BCSCP, explores current developments in the peptide space and what pharmacists need to know amid FDA decision-making processes.
This new, nonprescription therapy expands eye relief options for patients in need of apraclonidine eye drop formulations.
Advertisement
Advertisement